Mon. 6 May 2024, 3:47am ET
Benzinga
News
- -A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate-
- -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US-
- -APA Annual Meeting, the largest psychiatric gathering in the world, is the first scientific presentation of MM120 Phase 2b data-